

Shiv K Singh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5136340/publications.pdf>

Version: 2024-02-01

29
papers

1,644
citations

394390

19
h-index

454934

30
g-index

30
all docs

30
docs citations

30
times ranked

2590
citing authors

#	ARTICLE	IF	CITATIONS
1	Organoids at the PUB: The Porcine Urinary Bladder Serves as a Pancreatic Niche for Advanced Cancer Modeling. <i>Advanced Healthcare Materials</i> , 2022, 11, e2102345.	7.6	7
2	NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression. <i>Gut</i> , 2022, 71, 2561-2573.	12.1	15
3	TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 3451.	3.7	5
4	TNF- α -producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. <i>Nature Cancer</i> , 2021, 2, 1185-1203.	13.2	46
5	Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer. <i>Cells</i> , 2021, 10, 3463.	4.1	6
6	Depletion of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer. <i>Cancers</i> , 2020, 12, 1978.	3.7	27
7	EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of <i>GATA6</i> . <i>Cancer Research</i> , 2020, 80, 4620-4632.	0.9	56
8	Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma. <i>Frontiers in Immunology</i> , 2020, 11, 1402.	4.8	156
9	Microenvironmental Determinants of Pancreatic Cancer. <i>Physiological Reviews</i> , 2020, 100, 1707-1751.	28.8	156
10	Secretion of functionally active complement factor H related protein 5 (FHR5) by primary tumour cells derived from Glioblastoma Multiforme patients. <i>Immunobiology</i> , 2019, 224, 625-631.	1.9	9
11	SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer. <i>EBioMedicine</i> , 2019, 48, 161-168.	6.1	16
12	Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 201.	4.4	14
13	Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer. <i>Cells</i> , 2019, 8, 563.	4.1	5
14	Human Surfactant Protein D Suppresses Epithelial-to-Mesenchymal Transition in Pancreatic Cancer Cells by Downregulating TGF- β 2. <i>Frontiers in Immunology</i> , 2018, 9, 1844.	4.8	15
15	A Recombinant Fragment of Human Surfactant Protein D induces Apoptosis in Pancreatic Cancer Cell Lines via Fas-Mediated Pathway. <i>Frontiers in Immunology</i> , 2018, 9, 1126.	4.8	33
16	Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF- β 2 Pathway. <i>Cell Reports</i> , 2016, 16, 950-966.	6.4	49
17	GSK-3 β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 491-502.	4.1	44
18	Antithetical NFATc1/Sox2 and p53/miR200 signaling networks govern pancreatic cancer cell plasticity. <i>EMBO Journal</i> , 2015, 34, 517-530.	7.8	87

#	ARTICLE	IF	CITATIONS
19	Inflammation-Induced NFATc1-STAT3 Transcription Complex Promotes Pancreatic Cancer Initiation by Kras/G12D. <i>Cancer Discovery</i> , 2014, 4, 688-701.	9.4	108
20	Senescence in pancreatic carcinogenesis: from signalling to chromatin remodelling and epigenetics. <i>Gut</i> , 2013, 62, 1364-1372.	12.1	22
21	Restricted Heterochromatin Formation Links NFATc2 Repressor Activity With Growth Promotion in Pancreatic Cancer. <i>Gastroenterology</i> , 2012, 142, 388-398.e7.	1.3	90
22	Disruption of a Nuclear NFATc2 Protein Stabilization Loop Confers Breast and Pancreatic Cancer Growth Suppression by Zoledronic Acid. <i>Journal of Biological Chemistry</i> , 2011, 286, 28761-28771.	3.4	24
23	Sequential Activation of NFAT and c-Myc Transcription Factors Mediates the TGF- β 2 Switch from a Suppressor to a Promoter of Cancer Cell Proliferation. <i>Journal of Biological Chemistry</i> , 2010, 285, 27241-27250.	3.4	86
24	Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. <i>Cancer Letters</i> , 2010, 287, 109-116.	7.2	57
25	Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. <i>Journal of Cellular Biochemistry</i> , 2009, 108, 106-116.	2.6	34
26	Therapeutic effects of recombinant forms of full-length and truncated human surfactant protein D in a murine model of invasive pulmonary aspergillosis. <i>Molecular Immunology</i> , 2009, 46, 2363-2369.	2.2	24
27	Fatal attraction: why breast cancer cells home to bone. <i>Breast Cancer Research</i> , 2008, 10, 101.	5.0	34
28	DNA-Microarray Technology: Comparison of Methodological Factors of Recent Technique Towards Gene Expression Profiling. <i>Critical Reviews in Biotechnology</i> , 2008, 28, 239-251.	9.0	9
29	Osteoporosis in Patients With Diabetes Mellitus. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1317-1328.	2.8	406